Background
Phase 3, open-label, randomized controlled trial (FLAIR; UK NCRI). N=771 treatment-naive CLL patients, age ≤75, ECOG PS 0–2. Randomized to ibrutinib + rituximab (IR), ibrutinib monotherapy (I), or FCR (fludarabine + cyclophosphamide + rituximab). The original design compared IR vs FCR; the protocol was amended to add an ibrutinib monotherapy arm and an MRD-guided ibrutinib + venetoclax arm. Primary endpoint: PFS.
Interventions and follow up
Arm A: Ibrutinib 420 mg PO daily + rituximab 375 mg/m² IV cycle 1 then 500 mg/m² cycles 2–6 (IR); 6 cycles then ibrutinib continuation
Arm B: Fludarabine 24 mg/m²/d PO days 1–5 + cyclophosphamide 150 mg/m²/d PO days 1–5 + rituximab (FCR); 6 cycles
Primary endpoint: PFS (IR vs FCR initially; ibrutinib arms vs FCR in updated analysis)
Median follow-up: 52.7 months (NEJM 2024); ~6 years (NEJM 2025)
Arm B: Fludarabine 24 mg/m²/d PO days 1–5 + cyclophosphamide 150 mg/m²/d PO days 1–5 + rituximab (FCR); 6 cycles
Primary endpoint: PFS (IR vs FCR initially; ibrutinib arms vs FCR in updated analysis)
Median follow-up: 52.7 months (NEJM 2024); ~6 years (NEJM 2025)
Results
PFS (IR vs FCR): Not reached vs 67.7 months, HR 0.44, P<.001 (NEJM 2024)
OS (IR vs FCR): HR 0.66, P=.026
PFS (ibrutinib mono vs FCR): HR 0.32, P<.001 (NEJM 2025)
PFS (MRD-guided ibrutinib + venetoclax vs FCR): HR 0.22, P<.001 (NEJM 2025)
IGHV subgroups (IR vs FCR): unmutated HR 0.29 (marked benefit); mutated HR 0.64 (numerically smaller)
OS (IR vs FCR): HR 0.66, P=.026
PFS (ibrutinib mono vs FCR): HR 0.32, P<.001 (NEJM 2025)
PFS (MRD-guided ibrutinib + venetoclax vs FCR): HR 0.22, P<.001 (NEJM 2025)
IGHV subgroups (IR vs FCR): unmutated HR 0.29 (marked benefit); mutated HR 0.64 (numerically smaller)
Adverse events
Hematologic: FCR grade ≥3 neutropenia 58%; secondary myeloid neoplasms 7 (FCR) vs 0 (IR)
Cardiovascular (IR): AFib any grade 14%, hypertension grade ≥3 12%, major hemorrhage 7%
Infections: Grade ≥3 infections 16% (FCR)
Other: Fewer Richter transformations with ibrutinib arms (1 vs 4 FCR); ibrutinib discontinuation for toxicity ~20% at 4 years
Cardiovascular (IR): AFib any grade 14%, hypertension grade ≥3 12%, major hemorrhage 7%
Infections: Grade ≥3 infections 16% (FCR)
Other: Fewer Richter transformations with ibrutinib arms (1 vs 4 FCR); ibrutinib discontinuation for toxicity ~20% at 4 years
Conclusions
Ibrutinib-based frontline therapy (IR and ibrutinib monotherapy) significantly improved PFS and OS versus FCR in treatment-naive CLL, with particularly large benefit in IGHV-unmutated patients. MRD-guided ibrutinib + venetoclax demonstrated the deepest PFS benefit over FCR. FCR is no longer appropriate first-line therapy for fit patients given these OS data.
Key Limitations
Rituximab adds to ibrutinib (IR) without clear benefit over ibrutinib alone by cross-trial comparison; FLAIR does not directly compare IR vs ibrutinib monotherapy (sequential cohorts). The FCR comparator is less relevant in the era of zanubrutinib and venetoclax-based doublets. Open-label design. Protocol amendments adding ibrutinib and MRD-guided arms complicate the original statistical hierarchy. Long-term ibrutinib toxicity (AFib, hypertension, hemorrhage) is a limitation versus fixed-duration approaches.
Clinical Context
FLAIR, alongside ECOG E1912 and Alliance A041202, established BTKi-based frontline therapy as superior to FCR, with IGHV-unmutated patients deriving the largest benefit. With RESONATE-2, iLLUMINATE, ECOG E1912, and FLAIR all favoring BTKi, FCR is now reserved for young IGHV-mutated patients without del(17p)/TP53 at select centers. Zanubrutinib has largely replaced ibrutinib given superior cardiac tolerability (ALPINE). ESMO-MCBS: 4 (IR vs FCR).